Published customer image:
LYNX Rapid HRP Antibody Conjugation Kit (LNK001P) used to conjugate detection antibody reagent prior to use in an anti Drug Antibody ELISA.
Image caption:
Pembrolizumab drug and anti-drug antibody (ADA) levels in a clinical cohort. Data generated from patients with melanoma treated with pembrolizumab (n=41). (A) Pembrolizumab drug level at baseline (B/L), just prior to Cycle 2 (T1) and last available timepoint (T2; Median Cycle 7 or 21 weeks IQR Cycle 4-13). (B) pembrolizumab ADA were detectable at B/L, T1 and T2. Patients with an ADA at T1 had higher pembrolizumab drug levels (*p<0.05).

From: Sasson SC, Wilkins LE, Watson RA, Jolly C, Brain O, Klenerman P, Olsson-Brown A, Fairfax BP.
Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma.
.
doi: 10.1038/s41598-021-98700-7..
This image is from an open access article distributed under terms of a.

Published customer image:
LYNX Rapid HRP Antibody Conjugation Kit (LNK001P) used to conjugate detection antibody reagent prior to use in an anti Drug Antibody ELISA.
Image caption:
Pembrolizumab drug and anti-drug antibody (ADA) levels in a clinical cohort. Data generated from patients with melanoma treated with pembrolizumab (n=41). (A) Pembrolizumab drug level at baseline (B/L), just prior to Cycle 2 (T1) and last available timepoint (T2; Median Cycle 7 or 21 weeks IQR Cycle 4-13). (B) pembrolizumab ADA were detectable at B/L, T1 and T2. Patients with an ADA at T1 had higher pembrolizumab drug levels (*p<0.05).

From: Sasson SC, Wilkins LE, Watson RA, Jolly C, Brain O, Klenerman P, Olsson-Brown A, Fairfax BP.
Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma.
Sci Rep. 2021 Sep 28;11(1):19253.
doi: 10.1038/s41598-021-98700-7..
This image is from an open access article distributed under terms of a Creative Commons Attribution License.

Published customer image:
LYNX Rapid HRP Antibody Conjugation Kit (LNK001P) used to conjugate detection antibody reagent prior to use in an anti Drug Antibody ELISA.
Image caption:
Pembrolizumab drug and anti-drug antibody (ADA) levels in a clinical cohort. Data generated from patients with melanoma treated with pembrolizumab (n=41). (A) Pembrolizumab drug level at baseline (B/L), just prior to Cycle 2 (T1) and last available timepoint (T2; Median Cycle 7 or 21 weeks IQR Cycle 4-13). (B) pembrolizumab ADA were detectable at B/L, T1 and T2. Patients with an ADA at T1 had higher pembrolizumab drug levels (*p<0.05).

From: Sasson SC, Wilkins LE, Watson RA, Jolly C, Brain O, Klenerman P, Olsson-Brown A, Fairfax BP.
Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma.
Sci Rep. 2021 Sep 28;11(1):19253.
doi: 10.1038/s41598-021-98700-7..
This image is from an open access article distributed under terms of a Creative Commons Attribution License.

Published customer image:
LYNX Rapid HRP Antibody Conjugation Kit (LNK001P) used to conjugate detection antibody reagent prior to use in an anti Drug Antibody ELISA.
Image caption:
Pembrolizumab drug and anti-drug antibody (ADA) levels in a clinical cohort. Data generated from patients with melanoma treated with pembrolizumab (n=41). (A) Pembrolizumab drug level at baseline (B/L), just prior to Cycle 2 (T1) and last available timepoint (T2; Median Cycle 7 or 21 weeks IQR Cycle 4-13). (B) pembrolizumab ADA were detectable at B/L, T1 and T2. Patients with an ADA at T1 had higher pembrolizumab drug levels (*p<0.05).

From: Sasson SC, Wilkins LE, Watson RA, Jolly C, Brain O, Klenerman P, Olsson-Brown A, Fairfax BP.
Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma.
Sci Rep. 2021 Sep 28;11(1):19253.
doi: 10.1038/s41598-021-98700-7..
This image is from an open access article distributed under terms of a Creative Commons Attribution License.